POCI

Business Context and Reporting Period

Company: Precision Optics Corporation, Inc. (POCI)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended September 30, 2025 (Q1 Fiscal 2026)
Business Overview: Developer and manufacturer of advanced optical instruments for medical devices and defense/aerospace markets. Operations include systems manufacturing, engineering design, Ross Optical components, and a micro-optics laboratory.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 59.2% year-over-year, driven primarily by a 297.3% surge in Systems Manufacturing revenue ($4.87M vs $1.23M). This was partially offset by significant declines in Engineering Design Services (-59.3%) and Micro Optics Lab (-76.5%).
• Margin Compression: Gross margin contracted significantly from 26.6% to 14.2%. Management attributed this to lower utilization of engineering resources, low yields on single-use medical device lines, and delays in Micro Optics Lab reorders.
• Expense Increases: Selling, General, and Administrative (SG&A) expenses rose 13.6% to $2.23M, largely due to increased stock-based compensation, severance, and consulting fees. R&D expenses decreased 22.2% to $311,840.
• Balance Sheet Shifts: Total assets increased to $22.4M from $19.8M, driven by a significant increase in operating lease right-of-use assets ($2.5M vs $142k) and inventory buildup ($3.88M vs $3.56M). Total liabilities rose to $11.5M, primarily due to new operating lease liabilities.

Outlook, Risks, and Contingencies

• Liquidity Position: Management believes current cash, operating cash flow, and potential capital market access are sufficient for 12 months. However, they noted that cash from operations alone may be insufficient, potentially requiring external financing.
• Debt Covenants: The company is currently not in compliance with its minimum Debt Service Coverage ratio covenant (1.20x) as of September 30, 2025. Future advances are contingent on achieving this ratio. The lender previously waived compliance for the fiscal year ending June 30, 2025, subject to an equity raise which was completed in February 2025.
• Capital Expenditures: Significant cash was used for investing activities ($301,789), primarily for purchases of fixed assets and patent costs.
• Contractual Commitments: The company has open purchase orders totaling approximately $7.4 million and significant future minimum lease payments ($3.84M).
• Forward-Looking Statements: The filing includes standard disclaimers regarding risks such as customer demand, supply chain issues, and the ability to raise capital.

Investor Verification Checklist

• Covenant Compliance: Verify the status of the Debt Service Coverage ratio waiver and the specific terms required to regain full compliance with Main Street Bank.
• Margin Recovery: Assess the timeline for improving gross margins, specifically regarding yield rates on single-use medical devices and the resumption of Micro Optics Lab orders.
• Revenue Mix Sustainability: Determine if the 297% increase in Systems Manufacturing revenue is a one-time scaling event or indicative of a sustained shift in the business model away from lower-margin engineering services.
• Working Capital Needs: Review the $7.4M in open purchase orders against current cash reserves ($1.39M) to evaluate immediate liquidity pressure.
• Lease Obligations: Analyze the impact of the new long-term operating leases (South Portland, Maine and Littleton, Massachusetts) on future cash flow requirements.